Cargando…

Benefits of chronic total coronary occlusion percutaneous intervention in patients with heart failure and reduced ejection fraction: insights from a cardiovascular magnetic resonance study

BACKGROUND: Chronic total occlusion percutaneous coronary intervention (CTO-PCI) can improve angina and left ventricular ejection fraction (LVEF). These benefits were not assessed in populations with heart failure with reduced ejection fraction (HFrEF). We studied the effect of CTO-PCI on left ventr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardona, Montserrat, Martín, Victoria, Prat-Gonzalez, Susanna, Ortiz, José Tomás, Perea, Rosario Jesús, de Caralt, Teresa Maria, Masotti, Mónica, Pérez-Villa, Félix, Sabaté, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097417/ https://www.ncbi.nlm.nih.gov/pubmed/27814739 http://dx.doi.org/10.1186/s12968-016-0287-5

Ejemplares similares

T1 mapping: characterisation of myocardial interstitial space
por: Perea, Rosario J., et al.
Publicado: (2014)

Prognostic Value of Soluble AXL in Serum from Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction
por: Cristóbal, Helena, et al.
Publicado: (2023)

Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions
por: El Awady, Waleed Salem, et al.
Publicado: (2020)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Improving the robustness of MOLLI T1 maps with a dedicated motion correction algorithm
por: Delso, Gaspar, et al.
Publicado: (2021)

Physiological benefits evaluated by quantitative flow ratio in patients with reduced left ventricular ejection fraction who underwent percutaneous coronary intervention
por: Zhong, Jiaxin, et al.
Publicado: (2020)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Benefits of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention
por: Shiono, Yasutsugu
Publicado: (2022)

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction
por: Choi, Ki Hong, et al.
Publicado: (2019)

Clinical predictors of microvascular obstruction by delayed enhanced CMR in STEMI patients
por: Izquierdo, Maria M, et al.
Publicado: (2011)

Clinical predictors of microvascular obstruction by delayed enhanced CMR in STEMI patients
por: Pérez, José T Ortiz, et al.
Publicado: (2011)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

In-hospital outcomes after primary percutaneous coronary intervention according to left ventricular ejection fraction
por: Vakili, Hossein, et al.
Publicado: (2014)

Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
por: Riccardi, Mauro, et al.
Publicado: (2022)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Benefits of successful percutaneous coronary intervention in chronic total occlusion patients with diabetes
por: Zhao, Shuai, et al.
Publicado: (2022)

Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion
por: Yang, Lulu, et al.
Publicado: (2022)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)

Safety, Efficacy and Prognostic Benefit of Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction
por: Johner, Nicolas, et al.
Publicado: (2022)

Multivessel spontaneous coronary artery dissection involving the left main coronary artery: a case report
por: Cepas-Guillén, Pedro L, et al.
Publicado: (2019)

The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention
por: Banning, Adrian P, et al.
Publicado: (2020)

Diabetes Associated With Greater Ejection Fraction Improvement After Revascularization in Patients With Reduced Ejection Fraction
por: Wang, Shaoping, et al.
Publicado: (2021)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction
por: Shahnazaryan, Syuzanna, et al.
Publicado: (2023)

Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction
por: Alidoosti, M, et al.
Publicado: (2008)

Myocardial Contraction Fraction is Superior to Ejection Fraction in Predicting Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction
por: Abdellatif, Yasser A., et al.
Publicado: (2022)

Role of Circulating Angiotensin Converting Enzyme 2 in Left Ventricular Remodeling following Myocardial Infarction: A Prospective Controlled Study
por: Ortiz-Pérez, José T., et al.
Publicado: (2013)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Zach, Veronika, et al.
Publicado: (2020)

Data on clinical characteristics of a heart failure patients’ cohort with reduced ejection fraction and analysis of the circulating values of five different heart failure biomarkers; high sensitivity troponin T, galectin-3, C-terminal propeptide of type I procollagen, soluble AXL and BNP()
por: Batlle, M., et al.
Publicado: (2016)

Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience
por: Blanco, Carola, et al.
Publicado: (2023)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
por: Oh, Ji‐Hye, et al.
Publicado: (2022)

Cardiovascular Benefits of Resistance Training in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review
por: Danduboyina, Anirudh, et al.
Publicado: (2023)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_90rtdbl60m653djcc8fj1q83kl